BCL2A1 and Langerhans cell histiocytosis: The combination of anti-IL-17A neutralizing antibodies with low dose of VBL completely inhibited the expression of BCL2A1 (Figure 5A) and abrogated DC survival (<7%) of Mo-DCs from LCH patients (Figure 5B).